Dr. Marina M. Roytman, MD

Dr. Roytman practices at Community Regional Medical Center in Fresno, California, part of Community Health System.

Dr. Roytman's NPI, 1770521452, was assigned on June 3, 2006. Dr. Roytman graduated from Oregon Health Sciences University School of Medicine in 2000. Dr. Roytman holds California license C148700.

Dr. Roytman's primary practice is Community Regional Medical Center, at 2823 Fresno Street, Fresno, CA 93721 in Fresno County. The practice phone is (559) 459-6000.

Dr. Roytman's primary practice is Community Regional Medical Center in Fresno, California, part of Community Health System. Dr. Roytman is also affiliated with Clovis Community Medical Center. The medical group on file is Inspire Health Medical Group. Dmand AI also links Dr. Roytman to 2 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Roytman practices, 6 sites in all. Vendor and product names are available with a free account.

Hepatology is Dr. Roytman's primary specialty in the NPI Registry, under taxonomy code 207RI0008X. Dr. Roytman is licensed in California.

CMS data shows 451 Medicare services from Dr. Roytman across 6 procedure codes in 2024, for 339 Medicare patients. Medicare paid $33,848 for them.

CMS counts 339 Medicare patients who saw Dr. Roytman in 2024. The largest group is 65 to 74, with 202 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 37% are also on Medicaid. Their average risk score is 1.68, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Roytman's median patient age at 59, with 52% women.

In 2024, Dr. Roytman wrote 547 Medicare Part D claims for 95 patients. 75% of them were for generic drugs. CMS names the drug for 485 of them, across 12 drugs with 11 or more claims each, at $510,344 in total drug cost. In 2023, CMS named 373 claims across 12 drugs.

Dr. Roytman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Roytman as offering telehealth.

Dmand AI links 40 papers to Dr. Roytman, published from 2015 to 2025. 2023 was the busiest year, with 9. The most frequent topics are Biopsy, Antiviral Agents and COVID-19. Dr. Roytman has published most often in Hawaii J Med Public Health. Dr. Roytman's most frequent co-authors are Aalam Sohal, Hunza Chaudhry, MD and Nimrat Dhillon, MBBS.

Dmand AI links Dr. Roytman to 3 clinical trials. Conditions studied include Non-alcoholic Fatty Liver Disease, Hepatitis D and Liver Cirrhosis.

CMS Open Payments shows 388 general payments to Dr. Roytman from 20 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 55% of the total. Gilead Sciences, Inc. paid the most, $107,260.

Dr. Roytman graduated from Oregon Health Sciences University School of Medicine in 2000.